Return on **Innovation**

Global health R&D delivers for Kansas

GHTC global health technologies coalition

US government (USG) investment in global health R&D has delivered

$17.7 million
to Kansas research institutions*

200+ new jobs
for Kansas†

Kansas's top global health R&D institutions by USG funding*

ORGANIZATION	FUNDING
University of Kansas	**$10.6 million**
Kansas State University	**$6.8 million**
Children's Mercy Hospital Kansas	**$340 thousand**

Global health R&D at work in the Sunflower State


PATH/Gabe Bienczycki

Researchers at the University of Kansas (KU) are working to develop a low-cost vaccine manufacturing platform for use in the world's poorest nations. The researchers are collaborating with partners to standardize the development of new vaccines. Their goal is to create several vaccine candidates that cannot only be produced inexpensively but also remain stable to ensure their potency during storage, transport, and distribution. Affordable and reliable vaccines are a crucial element of disease prevention programs around the world. Delivered effectively, they can save lives and improve the health of entire populations. The KU team is also working on a needle-free vaccination method to be used with several currently available vaccines.

Neglected diseases in Kansas‡

HIV diagnoses	**1,289**
Tuberculosis cases	**396**
West Nile cases	**339**
Malaria cases	**61**
Chikungunya cases	**27**

Kansas industry in global health R&D

Bayer: Shawnee

Celgene: Overland Park

Orbis Biosciences: Lenexa

Kansas's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES§

89¢ of every dollar
the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghtcoalition.org for additional details.

‡ Centers for Disease Control and Prevention: HIV diagnoses 2008-2016, Tuberculosis cases 2008-2016, West Nile virus disease cases 2008-2016, Malaria cases 2008-2014, Chikungunya virus disease cases 2014-2017.

§ Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶ NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.